BioAtla 3021

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Trial overview

Topic

BioAtla 3021

Description

This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3021 alone and in combination with nivolumab in patients with advanced solid tumors. Phase 1 will comprise 2 sequential parts—dose escalation and dose expansion—and is designed to evaluate the safety and tolerability of BA3021 in patients with advanced solid tumors and to identify the MTD and/or RP2D for BA3021. Phase 2 is an open-label study to evaluate the efficacy and safety of BA3021 alone and in combination with nivolumab in patients with metastatic non-small cell lung cancer (NSCLC) and melanoma.

Physicians

Contact

Florida East Coast - Aventura

Peggy Mouradian & Nancy Joseph